Currency In USD
| Previous Close | 40.17 |
| Open | 43.53 |
| Day High | 43.53 |
| Day Low | 39.87 |
| 52-Week High | 45.22 |
| 52-Week Low | 22.29 |
| Volume | 0 |
| Average Volume | 329,328 |
| Market Cap | 503.77M |
| PE | 24.95 |
| EPS | 1.61 |
| Moving Average 50 Days | 41.95 |
| Moving Average 200 Days | 33.57 |
| Change | 0 |
Data not available
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
GlobeNewswire Inc.
Feb 09, 2026 2:53 PM GMT
Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value RightEMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty agg
XOMA Royalty Announces CFO Transition
GlobeNewswire Inc.
Jan 12, 2026 12:30 PM GMT
EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other prof
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
GlobeNewswire Inc.
Dec 30, 2025 12:30 PM GMT
– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda’s exter